Matrix Metalloproteinase Pharmacogenomics in Non-Small-Cell Lung Carcinoma

• Jemal A , SiegelR, XuJ, WardE: Cancer statistics, 2010.CA Cancer J. Clin.60(5) , 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Scagliotti G , NovelloS: Adjuvant chemotherapy after complete resection for early stage NSCLC.Lung Cancer42(Suppl. 1) , S47–S51 (2003).
   PubMed Web of Science ®Google Scholar
• Page-McCaw A , EwaldAJ, WerbZ: Matrix metalloproteinases and the regulation of tissue remodelling.Nat. Rev. Mol. Cell Biol.8(3) , 221–233 (2007).
   PubMed Web of Science ®Google Scholar
• Overall CM , KleifeldO: Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.Nat. Rev. Cancer6(3) , 227–239 (2006).
   PubMed Web of Science ®Google Scholar
• Egeblad M , WerbZ: New functions for the matrix metalloproteinases in cancer progression.Nat. Rev. Cancer2(3) , 161–174 (2002).
   PubMed Web of Science ®Google Scholar
• Cho NH , HongKP, HongSH, KangS, ChungKY, ChoSH: MMP expression profiling in recurred stage IB lung cancer.Oncogene23(3) , 845–851 (2004).
   PubMed Web of Science ®Google Scholar
• Delebecq TJ , PorteH, Zerimech Fet al.: Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin. Cancer Res.6(3) , 1086–1092 (2000).
   PubMed Web of Science ®Google Scholar
• Hofmann HS , HansenG, Richter Get al.: Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin. Cancer Res.11(3) , 1086–1092 (2005).
   PubMed Web of Science ®Google Scholar
• Muller D , BreathnachR, Engelmann Aet al.: Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int. J. Cancer48(4) , 550–556 (1991).
   PubMed Web of Science ®Google Scholar
• Pritchard SC , NicolsonMC, Lloret Cet al.: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol. Rep.8(2) , 421–424 (2001).
   PubMed Web of Science ®Google Scholar
• Shah SA , SpinaleFG, IkonomidisJS, StroudRE, ChangEI, ReedCE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung.J. Thorac. Cardiovasc. Surg.139(4) , 984–990 (2010).
   PubMed Web of Science ®Google Scholar
• Tokuraku M , SatoH, MurakamiS, OkadaY, WatanabeY, SeikiM: Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis.Int. J. Cancer64(5) , 355–359 (1995).
   PubMed Web of Science ®Google Scholar
• Bramhall SR , SchulzJ, NemunaitisJ, BrownPD, BailletM, BuckelsJA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.Br. J. Cancer87(2) , 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Bramhall SR , HallisseyMT, Whiting Jet al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer86(12) , 1864–1870 (2002).
   PubMed Web of Science ®Google Scholar
• Fingleton B : Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects.Expert Opin. Ther. Targets7(3) , 385–397 (2003).
   PubMed Web of Science ®Google Scholar
• Sherry ST , WardM, SirotkinK: dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation.Genome Res.9(8) , 677–679 (1999).
   PubMed Web of Science ®Google Scholar
• Ponomarenko JV , OrlovaGV, Merkulova TIet al.: rSNP_Guide: an integrated database-tools system for studying SNPs and site-directed mutations in transcription factor binding sites. Hum. Mutat.20(4) , 239–248 (2002).
   PubMed Web of Science ®Google Scholar
• Ye S : Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.Matrix Biol.19(7) , 623–629 (2000).
   PubMed Web of Science ®Google Scholar
• Tower GB , CoonCC, BenbowU, VincentiMP, BrinckerhoffCE: Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells.Biochim. Biophys. Acta1586(3) , 265–274 (2002).
   PubMed Web of Science ®Google Scholar
• Su L , ZhouW, Park Set al.: Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev.14(3) , 567–570 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas P , KhokhaR, ShepherdFA, FeldR, TsaoMS: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.J. Pathol.190(2) , 150–156 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang WQ , LinH, ZhouYA, WangYJ, ChengQS: [Association of MMP1 -1607(1G>2G)single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality].Zhonghua. Yi Xue Yi Chuan Xue Za Zhi.23(3) , 313–315 (2006).
   PubMedGoogle Scholar
• Zhu Y , SpitzMR, LeiL, MillsGB, WuX: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility.Cancer Res.61(21) , 7825–7829 (2001).
   PubMed Web of Science ®Google Scholar
• Yu C , ZhouY, MiaoX, XiongP, TanW, LinD: Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer.Cancer Res.64(20) , 7622–7628 (2004).
   PubMed Web of Science ®Google Scholar
• Yu C , PanK, Xing Det al.: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res.62(22) , 6430–6433 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou Y , YuC, Miao Xet al.: Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis26(6) , 1117–1121 (2005).
   PubMed Web of Science ®Google Scholar
• Ye S , ErikssonP, HamstenA, KurkinenM, HumphriesSE, HenneyAM: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression.J. Biol. Chem.271(22) , 13055–13060 (1996).
   PubMed Web of Science ®Google Scholar
• Fang S , JinX, Wang Ret al.: Polymorphisms in the MMP1and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis26(2) , 481–486 (2005).
   PubMed Web of Science ®Google Scholar
• Fang SM , JinX, Li Yet al.: [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer]. Ai. Zheng.24(3) , 305–310 (2005).
   PubMedGoogle Scholar
• Jormsjo S , WhatlingC, WalterDH, ZeiherAM, HamstenA, ErikssonP: Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients.Arterioscler. Thromb. Vasc. Biol.21(11) , 1834–1839 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang J , JinX, Fang Set al.: The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis26(10) , 1748–1753 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang B , YeS, Herrmann SMet al.: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation99(14) , 1788–1794 (1999).
   PubMed Web of Science ®Google Scholar
• Rollin J , ReginaS, Vourc‘h Pet al.: Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer56(2) , 273–280 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Y , FangS, Wei Let al.: No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer49(2) , 155–161 (2005).
   PubMed Web of Science ®Google Scholar
• Balbin M , FueyoA, Tester AMet al.: Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet.35(3) , 252–257 (2003).
   PubMed Web of Science ®Google Scholar
• Montel V , KleemanJ, AgarwalD, SpinellaD, KawaiK, TarinD: Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression.Cancer Res.64(5) , 1687–1694 (2004).
   PubMed Web of Science ®Google Scholar
• Yoon S , KuivaniemiH, Gatalica Zet al.: MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol.21(6) , 487–498 (2002).
   PubMed Web of Science ®Google Scholar
• González-Arriaga P , Lopez-CimaMF, Fernandez-Somoano Aet al.: Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer19(8) , 378 (2008).
   Google Scholar
• Hu Z , HuoX, Lu Det al.: Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin. Cancer Res.11(15) , 5433–5439 (2005).
   PubMed Web of Science ®Google Scholar
• Jin G , MiaoR, Hu Zet al.: Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. Int. J. Cancer124(9) , 2172–2178 (2009).
   PubMed Web of Science ®Google Scholar
• Su L , ZhouW, Asomaning Ket al.: Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis27(5) , 1024–1029 (2006).
   PubMed Web of Science ®Google Scholar
• Sauter W , RosenbergerA, Beckmann Let al.: Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol. Biomarkers Prev.17(5) , 1127–1135 (2008).
   PubMed Web of Science ®Google Scholar
• Sun T , GaoY, Tan Wet al.: Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression. Clin. Cancer Res.12(23) , 7009–7017 (2006).
   PubMed Web of Science ®Google Scholar
• McColgan P , SharmaP: Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects.Int. J. Cancer125(6) , 1473–1478 (2009).
   PubMed Web of Science ®Google Scholar
• Heist RS , MarshallAL, Liu Get al.: Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin. Cancer Res.12(18) , 5448–5453 (2006).
   PubMed Web of Science ®Google Scholar
• Scherf DB , DallyH, Muller Pet al.: Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis. Eur. Respir. J.35(2) , 381–390 (2010).
   PubMed Web of Science ®Google Scholar
• Galligioni E , FerroA: Angiogenesis and antiangiogenic agents in non-small cell lung cancer.Lung Cancer34(Suppl. 4) , S3–S7 (2001).
   PubMed Web of Science ®Google Scholar
• Reckamp KL , GardnerBK, Figlin RAet al.: Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J. Thorac. Oncol.3(2) , 117–124 (2008).
   PubMed Web of Science ®Google Scholar
• Aljada IS , RamnathN, Donohue Ket al.: Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol.22(16) , 3218–3229 (2004).
   PubMed Web of Science ®Google Scholar
• Dubinett SM , ElashoffD, MeyersonM: Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture?J. Clin. Oncol.22(16) , 3209–3211 (2004).
   PubMed Web of Science ®Google Scholar
• Gouyer V , ContiM, Devos Pet al.: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer103(8) , 1676–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Ylisirnio S , HoyhtyaM, Makitaro Ret al.: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin. Cancer Res.7(6) , 1633–1637 (2001).
   PubMed Web of Science ®Google Scholar
• Blons H , GadS, Zinzindohoue Fet al.: Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin. Cancer Res.10(8) , 2594–2599 (2004).
   PubMed Web of Science ®Google Scholar
• Han MK , PostmaD, Mannino DMet al.: Gender and chronic obstructive pulmonary disease: why it matters. Am. J. Respir. Crit. Care Med.176(12) , 1179–1184 (2007).
   PubMed Web of Science ®Google Scholar
• Mannino DM : COPD and lung cancer have come a long way …baby.Am. J. Respir. Crit. Care Med.176(2) , 108–109 (2007).
   PubMed Web of Science ®Google Scholar
• Nenan S , BoichotE, LagenteV, BertrandCP: Macrophage elastase (MMP-12): a pro-inflammatory mediator?Mem. Inst. Oswaldo Cruz100(Suppl. 1) , 167–172 (2005).
   PubMed Web of Science ®Google Scholar
• Gorrin Rivas MJ , AriiS, Furutani Met al.: Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology28(4) , 986–993 (1998).
   PubMed Web of Science ®Google Scholar
• Houghton AM , GrisolanoJL, Baumann MLet al.: Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res.66(12) , 6149–6155 (2006).
   PubMed Web of Science ®Google Scholar
• Inuzuka K , OgataY, NagaseH, ShirouzuK: Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.J. Surg. Res.93(2) , 211–218 (2000).
   PubMed Web of Science ®Google Scholar

▪ Website

• American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society, GA, USA (2010) www3.cancer.org/downloads/stt/cancer_facts_and_figures_2010.pdf
   Google Scholar